The use of iontophoresis in the administration of nicotine and new non-nicotine drugs through the skin for smoking cessation

Current Drug Discovery Technologies

Volumn 6, Issue 3, 2009, Pages 171-185

  Escobar Chávez, José Juan ^a,b   Merino, Virginia ^b   López Cervantes, Miriam ^a   Rodríguez Cruz, Isabel Marlen ^a   Quintanar Guerrero, David ^a   Ganem Quintanar, Adriana ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Antidepressants; Iontophoresis; Skin penetration; Smoking cessation

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; BACLOFEN; BUSPIRONE; CLOMIPRAMINE; CLONIDINE; CLORGYLINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; MECAMYLAMINE; MIANSERIN; MILACEMIDE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NORTRIPTYLINE; PARGYLINE; PHENETHYLAMINE; PLACEBO; RIMONABANT; SELEGILINE; SR 1417161 A; SUMATRIPTAN; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALCOHOL WITHDRAWAL; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; ELECTRIC POTENTIAL; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; IONTOPHORESIS; NICOTINE REPLACEMENT THERAPY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SKIN PENETRATION; SMOKING CESSATION; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ANIMALS; BUPROPION; DOSAGE FORMS; DRUGS, INVESTIGATIONAL; HUMANS; IONTOPHORESIS; MODELS, BIOLOGICAL; NICOTINE; NICOTINIC AGONISTS; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 69249149703     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309789054924     Document Type: Review

References (155)

1. http://www.cdc.gov/Tobacco/sgr/sgr-1964/sgr64.htm
2. http://www.who.int/tobacco/en
3. http://www.fctc.org
4. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321: 323-329
5. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239 (Pubitemid 40216240)
6. Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 1993; 61: 743-750
7. Maes HH, Sullivan PF, Bulik CM, Neale MC, Prescott CA. A twin study of genetic and environmental influences n tobacco initiation, regular tobacco use and nicotine dependence. Psychol Med 2004; 34: 1251-1261
8. Muñoz RF, Lenert LL, Delucchi K, et al. Toward evidence based internet interventios: A Spanish/English Web site for international smoking cessation trials. Nicotine Tob Res 2006; 8(1): 77-87. (Pubitemid 43307562)
9. Thun MJ, Apicalla LF, Henley SJ. Smoking vs. other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 2000; 284: 706-712
10. World Health Organization. Tobacco or Health: A Global Status Report. Geneva, Switzerland: World Health Organization 1997.
11. Blackford AL, Yang G, Hernandez-Avila M, et al. Cotinine concentration in smokers from different countries: Relationship with amount smoked and cigarette type. Cancer Epidemiol Biomarkers Prev 2006; 15(10): 1799-1804 (Pubitemid 44664251)
12. Sussman S, Dent CW. Five-year prospective prediction of self-initiated quitting of cigarette smoking of high-risk youth. Addict Behav 2007; 32: 1094-1098 (Pubitemid 46282290)
13. Sussman S. Effects of sixty-six adolescent tobacco use cessation trials and seventeen prospective studies of self-initiated quitting. Tobacco Induced Diseases 2002; 1: 35-81.
14. U.S. Department of Health and Human Services. Preventing tobacco use among young people: A report of the surgeon general. Rockville, MD: Public Health Service 1994.
15. U.S. Department of Health and Human Services. Reducing tobacco use: A report of the surgeon general. Atlanta, GA: Office on Smoking and Health 2000.
16. Panday S, Reddy SP, Ruiter RAC, Bergström E, de Vries H. Nicotine dependence and withdrawal symptoms among occasional smokers. J Adolesc Health 2007; 40: 144-150 (Pubitemid 46149364)
17. Perry CL, Eriksen MP, Giovino G. Tobacco use: a paediatric epidemic. Tob Control 1994; 3: 97-98.
18. Peto R, Lopez AD, Boreham J. Mortality from smoking in developed countries 1950-2000. Oxford, UK: Oxford University Press 2004.
19. Doll R, Peto R, Boreham J. Mortality in relation to smoking: 50 years' observations on male British doctors. Br Med J 2004; 328: 1519. (Pubitemid 38850305)
20. US Department of Health and Human Services. The Health Benefits of Smoking Cessation. Washington, DC, US: Government Printing Office 1990.
21. US Department of Health and Human Services. The Health Consequences of Smoking: Nicotine Addiction. Washington, DC, US: Government Printing Office 1988.
22. Royal College of Physicians. Nicotine Addiction in Britain: A Report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians 2000.
23. Foulds J, Burke M, Steinberg M. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004; 9: 39-53.
24. Benowitz NL. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 1988; 319: 1318-1330
25. Scherer G. Smoking behavior and compensation: a review of the literature. Psychopharmacology 1999; 145: 1-20. (Pubitemid 29339758)
26. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens. Nicotine Tob Res 2004; 6: 899-912.
27. Garret BE, Rose CA, Hennigfield JE. Tobacco addiction and pharmacological interventions. Expert Opin Pharmacother 2001; 2(10): 1545-1555
28. Stead L, Lancaster T. Nicotine replacement therapy for smoking cessation: Cochrane systematic review. Int J Epidemiol 2005; 34: 1001-1002 (Pubitemid 41535542)
29. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; 3: CD000146.
30. Frishman WH, Mitta W, Kupersmith A. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol Rev 2006; 14: 57-73. (Pubitemid 44378510)
31. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. Cancer J Clin 2005; 55(28): 1-99.
32. Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev 2006; 25(1): 59-71.
33. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Press 1994.
34. Tobacco Advisory Group of the Royal College of Physicians. Is nicotine a drug of addiction? Nicotine addiction in Britain. London: Royal College of Physicians of London 2000.
35. Giovino GA, Henningfield JE, Tomar SL, Escobedo LG, Slade J. Epidemiology of tobacco use and dependence. Epidemiol Rev 1995; 17: 48-65.
36. Benowitz NL. Nicotine addiction. Prim Care 1999; 26(61): 1-63.
37. U.S. Department of Health and Human Services. The health consequences of smoking: nicotine addiction. Rockville, MD: Office on Smoking and Health 1988.
38. Centers for Disease Control. Cigarette smoking among adults-United States. MMWR Morb Mortal Wkly Rep 2001; 50: 869-873
39. Centers for Disease Control. Smoking cessation during previous year among adults-United States. MMWR Morb Mortal Wkly Rep 1993; 42: 504-507
40. U.S. Department of Health and Human Services. The health benefits of smoking cessation: a report of the surgeon general. Rockville, MD: Office on Smoking and Health 1990.
41. Davison AG, Duffy M. Smoking habits of long-term survivors of surgery for lung cancer. Thorax 1982; 37(33): 1-33.
42. Van Berkel TF, van der Vlugt MJ, Boersma H. Characteristics of smokers and long-term changes in smoking behavior in consecutive patients with myocardial infarction. Prev Med 2000; 31: 732-741 (Pubitemid 32037335)
43. Anthonisen NR, Connett JE, Kiley JP. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the lung health study. JAMA 1994; 272: 1497-1505 (Pubitemid 24986688)
44. Ostroff J, Garland J, Moadel A. Cigarette smoking patterns in patients after treatment of bladder cancer. J Cancer Educ 2000; 15: 86-90. (Pubitemid 30418452)
45. Hogg RC, Raggenbass M, Bertrand D. Nicotinic acetylcholine receptors: from structure to brain function. Rev Physiol Biochem Pharmacol 2003; 147: 1-46.
46. Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 1999; 22: 555-561
47. Levin ED. The role of nicotinic acetylcholine receptors in cognitive function. In: Clementi F, Gotti C, Fornasari D, Eds. Handbook of experimental pharmacology: neuronal nicotinic receptors. New York: Springer-Verlag 2000, pp. 587-602.
48. Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol 2000; 393: 141-146 (Pubitemid 30193410)
49. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 1998; 138: 217-230
50. Picciotto MR. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci 2003; 24: 493-499
51. Levin ED, Bencan Z, Cerutti DT. Anxiolytic effects of nicotine in Zebrafish. Physiol Behav 2007; 90: 54-58
52. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification and anatomic localization. Psychopharmacology 2006; 184: 523-539
53. Rose JE, Corrigall WA. Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology 1997; 130: 28-40. (Pubitemid 27107782)
54. Zacny JP, Stitzer ML. Cigarette brand-switching: effects on smoke exposure and smoking behavior. J Pharmacol Exp Ther 1988; 246: 619-627 (Pubitemid 18208415)
55. Lundahl LH, Henningfield JE, Lukas SE. Mecamylamine blockade of both positive and negative effects of IV nicotine in human volunteers. Pharmacol Biochem Behav 2000; 66: 637-643
56. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001; 70: 439-446
57. Picciotto MR. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci 2003; 23: 494-499
58. Picciotto MR, Caldarone BJ, King SL, Zachariou V. Nicotinic receptors in the brain: Links between molecular biology and behavior. Neuropsychopharmacology 2000; 22: 451-465 (Pubitemid 30145613)
59. Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J Neurosci 2003; 23: 3176-3185
60. Leonard S, Bertrand D. Neuronal nicotinic receptors: from structure to function. Nicotine Tob Res 2001; 3: 203-223 (Pubitemid 32821649)
61. Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementti F, Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci 2002; 22: 8785-8789 (Pubitemid 35379047)
62. Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 2002; 53: 606-617
63. Marshall DL, Redfern PH, Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated animals. J Neurochem 1997; 68: 1511-1519
64. Fowler JS. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379: 733-736 (Pubitemid 26061736)
65. Fowler JS. Brain monoamine oxidase A: inhibition by cigarette smoke. Proc Natl Acad Sci USA 1996; 93: 14065-14069 (Pubitemid 26424246)
66. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003; 5: 13-25. (Pubitemid 36285465)
67. Shiffman S, Shadel WG, Niaura R, et al. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology (Berl) 2003; 166: 343-350 (Pubitemid 36469936)
68. Cousins MS. Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob Res 2001; 3: 123-129
69. Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: An evidence-based clinical practice guideline for tobacco cessation. Chest 2002; 121: 932-941
70. Fiore MC. The agency for health care policy and research smoking cessation clinical practice guidelines. J Am Med Assoc 1996; 275: 1270-1280 (Pubitemid 26118502)
71. Hughes JR, Goldstein MG, Hurt RD, Shiffman F. Recent advances in the pharmacotherapy of smoking. J Am Med Assoc 1999; 281: 72-76
72. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. J Am Med Assoc 1994; 27: 1940-1947 (Pubitemid 24177103)
73. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401.
74. Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry 1993; Monograph 1, 1: 2-14.
75. Balfour DJ. The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. Int J Clin Pract 2001; 55: 53-57
76. Tashkin D, Kanner R, Bailey W. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575 (Pubitemid 32488814)
77. Jorenby DE, Leischow SJ, Nides MA. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-691 (Pubitemid 29110752)
78. Hurt RD, Sachs DP, Glover ED. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195-1202
79. Breslau N, Kilbey M, Andreski P. Nicotine dependence, major depression, and anxiety in young adults. Arch Gen Psychiatry 1991; 48: 1069-1074
80. Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL. Depression and the dynamics of smoking: a national perspective. JAMA 1990; 264: 1541-1545
81. Patton GC, Carlin JB, Coffey C, Wolfe R, Hibbert M, Bowes G. Depression, anxiety, and smoking initiation: a prospective study over 3 years. Am J Publ Health 1998; 88: 1518-1522 (Pubitemid 28455761)
82. Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55: 683-690 (Pubitemid 28364383)
83. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158: 2035-2039 (Pubitemid 28465629)
84. Da Costa CL, Younes RN, Lourenco MT. Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest 2002; 122: 403-408
85. Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002; 59: 930-936
86. Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res 2005; 7: 491-499
87. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 1988; 21: 253-259 (Pubitemid 18205644)
88. Manhem P, Nilsson LH, Moberg AL, Wadstein J, Hokfelt B. Alcohol withdrawal: effects of clonidine treatment on sympathetic activity, the reninaldosterone system, and clinical symptoms. Alcohol Clin Exp Res 1985; 9: 238-243 (Pubitemid 15011399)
89. Covey LS, Glassman AH. A meta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation. Br J Addict 1991; 86: 991-998
90. Gourlay SG, Benowitz N. Is clonidine an effective smoking cessation therapy? Drugs 1995; 50: 197-207.
91. Niaura R. Transdermal clonidine for smoking cessation: a double-blind randomized dose-response study. Exp Clin Psychopharmacol 1996; 4: 285-291 (Pubitemid 26285668)
92. Nana AP. Clonidine for smoking cessation. J Med Assoc Thai 1998; 81: 87-93.
93. Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR. Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hyperten 2002: 16: 453-457 (Pubitemid 34790335)
94. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994; 56: 86-99.
95. Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of precessation therapy. Exp Clin Psychopharmacol 1998; 6: 331-343
96. Eissenberg T, Griffiths RR, Stitzer ML. Mecamylamine does not precipitate withdrawal in cigarette smokers. Psychopharmacology 1996; 127: 328-336 (Pubitemid 26356758)
97. Edwards NB, Murphy JK, Downs AD, Ackerman BJ, Rosenthal TL. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am J Psychiatry 1989; 146: 373-376
98. Berlin I, Said S, Spreux-Varoquaux O, et al. A reversible monoamine oxidase a inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 58: 444-452
99. George TP, Vessicchio JC, Termine A, et al. A preliminary trial of selegiline hydrochloride versus placebo for smoking cessation. Biol Psychiatry 2003; 53: 136-143 (Pubitemid 36126476)
100. Niaura R, Spring B, Borrelli B, et al. Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol 2002; 70: 887-896 (Pubitemid 34847977)
101. Killen JD, Fortmann SP, Schatzberg AF, et al. Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol 2000; 68: 883-889
102. Blondal T, Gudmundsson LJ, Tomasson K, et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation. Addiction 1999; 94: 1007-1015
103. Hitsman B, Pingitore R, Spring B, et al. Antidepressant pharmacotherapy helps some cigarette smokers more than others. J Consult Clin Psychol 1999; 67: 547-554 (Pubitemid 29379468)
104. Schneider NG, Olmstead RE, Steinberg C, Sloan K, Daims RM, Brown HB. Efficacy of buspirone in smoking cessation: a placebo-controlled trial. Clin Pharmacol Ther 1996; 60: 568-575 (Pubitemid 26414093)
105. Pomerleau OF. Endogenous opioids and smoking: A review of progress and problems. Psychoneuroendocrinology 1998; 23: 115-130 (Pubitemid 28248466)
106. Krishnan-Sarin S, Rosen MI, O'Malley SS. Naloxone challenge in smokers: Evidence for an opioid component in nicotine dependence. Arch Gen Psychiatry 1999; 56: 663-668 (Pubitemid 29315639)
107. Sutherland G, Stapleton JA, Russell MA, Feyerabend C. Naltrexone, smoking behavior and cigarette withdrawal. Psychopharmacology (Berl) 1995; 120: 418-425
108. Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. Addiction 1999; 94: 1227-1237 (Pubitemid 29385151)
109. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotinic enhancment of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995; 269: 1692-1696
110. Anonymous. Rimonabant SR 141716, SR 141716a. Drugs RD 2002; 3: 65-66
111. Paterson NE, Semenova S, Gasparini F, Markou A. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) 2003; 167: 257-264 (Pubitemid 36712972)
112. Rasmus SK, Calligaro DO, Czachura JF, et al. The novel 5-hydroxytryptamine 1A antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine. J Pharmacol Exp Ther 2000; 294: 688-700.
113. Andreoli M, Tessari M, Pilla M, Valerio E, Haggan JJ, Heidbreder CA. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003; 28: 1272-1280 (Pubitemid 41070897)
114. Decker MW, Meyer MD, Sullivan JP. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control (review). Expert Opin Investig Drugs 2001; 10: 1819-1830.
115. Fattore L, Cossu G, Martellotta MC, Fratta W. Baclofen antagonizes intravenous self administration of nicotine in mice and rats. Alcohol Alcohol 2002; 37: 495-498
116. Malin DH, Lake JR, Lin A, et al. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 2001; 68: 87-92. (Pubitemid 32239443)
117. Rein H. Experimental electroendosmotic studies on living human skin, Z Biol 1924; 81: 124-129
118. Langer R. Transdermal drug delivery: past progress, current status, and future prospects. Adv Drug Deliv Rev 2004; 56: 557-558 (Pubitemid 38326932)
119. Meyer BR, Kreis W, Eschbach J, Omara V, Rosen S, Sibalis D. Successful transdermal administration of therapeutic doses of a polypeptide to normal human volunteers. Clin Pharmacol Ther 1988; 44(6): 607-612 (Pubitemid 19036610)
120. Merino V, Kalia, YN, Guy RH. Transdermal therapy and diagnosis by iontophoresis. Trends Biotechnol 1997; 15: 288-290
121. Delgado-Charro MB, Guy RH. Transdermal iontophoresis for controlled drug delivery and noninvasive monitoring, S.T.P. Pharm Sci 2001; 11: 403-414 (Pubitemid 34016285)
122. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev 2004; 56: 619-658
123. Singh P, Liu P, Dinh SM. In Facilitated Transdermal Delivery by Iontophoresis. Bronaughm RL, Maibach HI, Eds. New York: Marcel Dekker 2002, pp. 353-376
124. Sage BH, Riviere JE. Model systems in iontophoresis-transport efficacy. Adv Drug Deliv Rev 1992; 9: 265-287
125. Williams AC, Barry BW. Skin absorption enhancers. Crit Rev Ther Drug Carrier Syst 1992; 9: 305-353
126. Williams AC, Barry BW. Terpenes and the lipid-protein partitioning theory of skin gpenetration enhancement. Pharm Res 1991; 8: 17-24.
127. Wang Y, Thakur R, Fan Q, Michniak B. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. Eur J Pharm Biopharm 2005; 60: 179-191 (Pubitemid 40804560)
128. Tierney MJ, Tamada JA, Potts RO, et al. The GlucoWatch biographer: a frequent automatic and noninvasive glucose monitor. Ann Med 2000; 32: 632-641
129. Mudry B, Guy RH, Delgado-Charro MB. Prediction of iontophoretic transport across the skin. J Control Rel 2006; 111: 362-367
130. Abramson HA, Engle MG. Skin reactions. XII. Patterns produced in the skin by electrophoresis of dyes. Arch Dermatol Syphilol 1941; 44: 190-200.
131. Grimmes S. Pathways of ionic flow through human skin in vivo. Acta Derm Venereol 1984; 64: 93-98 (Pubitemid 14130446)
132. Burnette RR, Ongpipattanakul B. Characterisation of the pore transport properties and tissue alteration of excised human skin during iontophoresis. J Pharm Sci 1988; 77: 132-137 (Pubitemid 18043957)
133. Cullander C, Guy RH. Sites of iontophoretic current flow into the skin: identification and characterisation with the vibrating probe electrode. J Invest Dermatol 1991; 97: 55-64.
134. Scott ER, Laplaza AI, White HS, Phipps JB. Transport of ionic species in skin: contribution of pores to the overall skin conductance. Pharm Res 1993; 10: 1699-1709
135. Wearley L, Liu J, Chien YW. Iontophoresis facilitated transdermal delivery of verapamil. II. Factors affecting reversibility of skin permeability. J Control Release 1989; 9: 231-242 (Pubitemid 19203717)
136. Yu H, Matsubayashi H, Amano T, Cai J-Q, Sasa M. Activation by nicotine of striatal neurons receiving excitatory input from the substantia nigra via dopamine release. Brain Res 2000; 872: 223-226 (Pubitemid 30618909)
137. Jinks SL, Simons CT, Dessirier J-M, Carstens MI, Antognini JF, Carstens E. c-fos induction in rat superficial dorsal horn following cutaneous application of noxious chemical or mechanical stimuli. Exp Brain Res 2002; 145: 261-269
138. Scuvee-Moreau JJ, Dresse AE. Effect of various antidepressant drugs on the spontaneous firing rate of locus coeruleus and dorsal raphe neurons of the rat. Eur J Pharmacol 1979; 57(2-3): 219-225
139. Zahn S, Leis S, Schick C, Schmelz M, Birklein F. No I̧- adrenoreceptor-induced C-fiber activation in healthy human skin. J Appl Physiol 2004; 96: 1380-1384
140. Dinenno FA, Masuki S, Joyner MJ. Impaired modulation of sympathetic I̧-adrenergic vasoconstriction in contracting forearm muscle of ageing men. J Physiol 2005; 567(1): 311-321 (Pubitemid 41167324)
141. Drumond PD. Prior iontophoresis of saline enhances vasoconstriction to phenylephrine and clonidine in the skin of the human forearm. Blackwell Science Ltd. Br J Clin Pharmacol 2002; 54: 45-50.
142. Taniguchi K, Yoshitake S, Iwasaka H, Honda, N, Oyama T. The effects of imipramine, amitriptyline and clonidine administered by iontophoresis on the pain threshold. Acta Anaesthesiol Belg 1995; 46(3-4): 121-125 (Pubitemid 26157586)
143. Meidan VM, Al-Khalili M, Michniak BB. Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers. Int J Pharm 2003; 264: 73-83. (Pubitemid 37297635)
144. Patel SR, Zhong H, Sharma A, Kalia YN. In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. Eur J Pharm Biopharm 2007; 66(2): 296-330
145. Femenía-Font A, Balaguer-Fernández C, Merino V, López-Castellano A. Combination strategies for enhancing transdermal absorption of sumatriptan through skin. Int J Pharm 2006; 323: 125-130 (Pubitemid 44397365)
146. Gronier B, Rasmussen K. Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat. Br J Pharmacol 1998; 124: 455-464
147. Tersigni TJ, Rosenberg HC. Local pressure application of cannabinoid agonists increases spontaneous activityof rat substantia nigra pars reticulate neuronswithout affecting response to iontophoretically applied GABA. Brain Res 1996; 733: 184-192
148. Lundberg PA, Oreland L, Engberg G. Inhibition of locus coeruleus neuronal activity by betaphenylethylamine. Life Sci 1985; 36(19): 1889-1896 (Pubitemid 15081170)
149. Godfraind JM. Microiontophoretic study with milacemide, a glycine precursor, on mammalian central nervous system cells. Br J Pharmacol 1990; 100(1): 119-125
150. Blier P, Chaput Y, de Montigny C. Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decrease the function of terminal 5-HT autoreceptors; an electrophysiological study in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1988; 337(3): 246-254 (Pubitemid 18124919)
151. Stimmel GL. Benzodiazepines in schizophrenia. Pharmacotherapy 1996; 16(6Pt 2):148S-51S.
152. Merino V, Micó-Albiñana T, Nácher A, Diéz-sales O, Herráez M, Merino-Sanjuán M. Enhancment of nortriptyline penetration through human epidermi: influence of chemical enhancers and iontophoresis. J Pharm Pharmacol 2008; 60(4): 415-420
153. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP.: Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005; 165(19): 2286-2292 (Pubitemid 41549926)
154. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004; (4): CD000031.
155. Candy M, Jones L, Williams R, Tookman A, King M. Psychostimulants for depression. Cochrane Database Syst Rev 2008; 16(2): CD006722.